AKT1 and non-small cell lung carcinoma: As expected, shikonin inhibited the growth of paclitaxel-resistant NSCLC through suppression of NEAT1 and Akt signaling, providing a fascinating opportunity for paclitaxel-resistant NSCLC treatment.